Viatris Inc. (VTRS) Stock Score, Valuation & Financial Research
Viatris Inc. is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 16/100.
Quick answer for VTRS
Viatris Inc. currently has a Wall Street Score of 16/100. The stored market price is $16.51. Its financial score is 9/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Viatris Inc. does
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics,
VTRS financial snapshot
- Wall Street Score:
- 16/100
- Current price:
- $16.51
- Market capitalization:
- $19.23B
- Revenue:
- $14.56B
- Net income:
- $-296.5M
- Free cash flow:
- $1.94B
- Cash:
- $1.80B
- Total debt:
- $14.34B
- EPS:
- -3.00
- Financial score:
- 9/100
- Valuation score:
- 0/100
- Revenue score:
- 9/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $1.94B, showing positive cash generation.
- The balance sheet shows $1.80B of cash versus $14.34B of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 9/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research VTRS
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.